Literature DB >> 29907885

Recognition and control of hypertension, diabetes, and dyslipidemia in patients with rheumatoid arthritis.

Luísa Lima Castro1, Cristina Costa Duarte Lanna2, Mariana Pimenta Rocha2, Antônio Luiz Pinho Ribeiro2, Rosa Weiss Telles2.   

Abstract

Absolute cardiovascular risk of an individual with rheumatoid arthritis (RA) is greater when compared to the general population, and several factors have proven to be important for the development of coronary artery disease (CAD) in these patients, including factors related to the underlying disease, such as the systemic inflammatory response, drugs used in its treatment, and a higher prevalence of traditional risk factors for CAD. Our aim is to describe the recognition and control frequencies of systemic arterial hypertension (SAH), dyslipidemia, and diabetes mellitus (DM) in RA patients. Patients with RA answered a questionnaire focused on their general knowledge of the risk factors for CAD, as well as on the recognition of the risk factors that they possess. The patient's information, collected from a structured medical record, was reviewed to evaluate the control of risk factors. Hundred and thirty-four patients were included in the study. One patient was excluded due to the impossibility of reviewing her medical records. Therefore, 133 patients remained in the study. Patients had a mean (SD) age of 57.3 (12.9) years. SAH was diagnosed in 88 subjects, with a recognition frequency of 89.8%, and 63.3% had desirable blood pressure control. Seventy-two patients were diagnosed with dyslipidemia; 68.1% recognized that they had dyslipidemia and 69.4% achieved desirable LDL-c control. Twenty-two patients had DM; 90.9% admitted being diabetic and 40.9% had desirable glycemic control. The frequencies of the CAD risk factor recognition and control were high in comparison to those described for the general population.

Entities:  

Keywords:  Cardiovascular risk factors; Coronary artery disease; Rheumatoid arthritis; Risk factors for coronary artery disease

Mesh:

Substances:

Year:  2018        PMID: 29907885     DOI: 10.1007/s00296-018-4084-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  31 in total

1.  [VI Brazilian Guidelines on Hypertension].

Authors: 
Journal:  Arq Bras Cardiol       Date:  2010-07       Impact factor: 2.000

2.  [V Brazilian Guidelines on Dyslipidemias and Prevention of Atherosclerosis].

Authors:  H T Xavier; M C Izar; J R Faria Neto; M H Assad; V Z Rocha; A C Sposito; F A Fonseca; J E dos Santos; R D Santos; M C Bertolami; A A Faludi; T L R Martinez; J Diament; A Guimarães; N A Forti; E Moriguchi; A C P Chagas; O R Coelho; J A F Ramires
Journal:  Arq Bras Cardiol       Date:  2013-10       Impact factor: 2.000

3.  Trends in prevalence, awareness, treatment and control of hypertension in urban communities in Chile.

Authors:  Eduardo Fasce; Ivone Campos; Pilar Ibáñez; Maritza Flores; Hernán Zárate; Oscar Román; Fabrizio Fasce
Journal:  J Hypertens       Date:  2007-09       Impact factor: 4.844

4.  Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study.

Authors:  Bharath Manu Akkara Veetil; Elena Myasoedova; Eric L Matteson; Sherine E Gabriel; Cynthia S Crowson
Journal:  J Rheumatol       Date:  2013-05-01       Impact factor: 4.666

5.  Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010.

Authors:  Fangjian Guo; Di He; Wei Zhang; R Grace Walton
Journal:  J Am Coll Cardiol       Date:  2012-07-11       Impact factor: 24.094

Review 6.  Trends in prevalence of hypertension in Brazil: a systematic review with meta-analysis.

Authors:  Rafael V Picon; Flávio D Fuchs; Leila B Moreira; Glaube Riegel; Sandra C Fuchs
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

7.  Cardiovascular risk management in rheumatoid arthritis: are we still waiting for the first step?

Authors:  Mike J L Peters; Michael T Nurmohamed
Journal:  Arthritis Res Ther       Date:  2013-03-19       Impact factor: 5.156

8.  Level of unawareness and management of diabetes, hypertension, and dyslipidemia among adults in Luxembourg: findings from ORISCAV-LUX study.

Authors:  Ala'a Alkerwi; Sybil Pagny; Marie-Lise Lair; Charles Delagardelle; Jean Beissel
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

9.  Management of hyperlipidemia among patients with rheumatoid arthritis in the primary care setting.

Authors:  Kashif Jafri; Lynne Taylor; Melissa Nezamzadeh; Joshua F Baker; Nehal N Mehta; Christie Bartels; Catherine T Williams; Alexis Ogdie
Journal:  BMC Musculoskelet Disord       Date:  2015-09-03       Impact factor: 2.362

10.  Dyslipidemia awareness, treatment, control and influence factors among adults in the Jilin province in China: a cross-sectional study.

Authors:  Huan He; Ya-qin Yu; Yong Li; Chang-gui Kou; Bo Li; Yu-chun Tao; Qing Zhen; Chang Wang; Joseph Sam Kanu; Xu-feng Huang; Mei Han; Ya-wen Liu
Journal:  Lipids Health Dis       Date:  2014-08-03       Impact factor: 3.876

View more
  2 in total

Review 1.  Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic.

Authors:  Sakir Ahmed; Armen Yuri Gasparyan; Olena Zimba
Journal:  Rheumatol Int       Date:  2021-01-03       Impact factor: 3.580

Review 2.  Physician Adherence to Treat-to-Target and Practice Guidelines in Rheumatoid Arthritis.

Authors:  Bogdan Batko; Krzysztof Batko; Marcin Krzanowski; Zbigniew Żuber
Journal:  J Clin Med       Date:  2019-09-08       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.